Skip to main content
. 2018 Jul 9;53(3):1043–1054. doi: 10.3892/ijo.2018.4477

Figure 2.

Figure 2

Effects of NT21MP on the expression of MYD88 or TP53INP1 in MCF-7 and MCF-7/PR cells. (A) Effects of NT21MP on the expression of MYD88 using RT-qPCR analysis, compared with the control groups. (B) Effects of NT21MP on the expression of TP53INP1 using RT-PCR analysis, compared with the control groups. (C) Western blot analysis was performed to identify the effects of NT21MP on the expression of MYD88 or TP53INP1 in MCF-7 and MCF-7/PR cells, compared with control groups. The results are representative of three independent experiments. **P<0.01, ***P<0.001 and ###P<0.001, compared with SDF-1α treatment. NT21MP; 21-residue peptide derived from viral macrophage inflammatory protein II; SDF-1α, stromal cell-derived factor-1α; PR, paclitaxel-resistant; MYD88, myeloid differentiation primary response gene 88; TP53INP1, tumor protein 53-induced nuclear protein 1; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.